Information Provided By:
Fly News Breaks for February 14, 2020
DXCM
Feb 14, 2020 | 07:51 EDT
Guggenheim analyst Christopher Pasquale said DexCom's Q4 report "caps off a truly impressive 2019 for the company. Expecting a repeat of that performance in 2020 is "probably unrealistic," but he still sees a long growth runway as CGM adoption continues to ramp and the company branches out into other patient groups, Pasquale tells investors.He increased his price target on DexCom shares to $300 from $245 and reiterates a Buy rating on the stock after earnings.
News For DXCM From the Last 2 Days
There are no results for your query DXCM
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.